Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL365424 | 1.00 | — | — | |
| Cyclooctane SCHEMBL27515472 | 1.00 | CA1 (0.33) | CA1CA2POLBTSHRKMT2A | |
| Cyclopentane SCHEMBL2198075 | 1.00 | CA1 (0.33) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL11357022 | 1.00 | — | — | |
| SCHEMBL254 | 0.82 | — | — | |
| SCHEMBL6681816 | 0.82 | — | — | |
| SCHEMBL9540531 | 0.82 | — | — | |
| SCHEMBL27986358 | 0.82 | CA5A (0.33) | CA1CA2CA7 | |
| Cyclopropane SCHEMBL28876799 | 0.80 | — | — | |
| Cyclohexane SCHEMBL11777586 | 0.80 | CA5A (0.42) | CA1CA2POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116328564-A | Method for preparing composite reverse osmosis membrane, composite reverse osmosis membrane prepared by method and application of composite reverse osmosis membrane | 沃顿科技股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-116120261-A | Preparation method of 3- [ (4-sulfadiazine-1-yl) methyl ] benzoic acid compound | 浙大宁波理工学院 | 2023-05-16 | — | — | CN | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| CN-119977980-A | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119998964-A | Self-poisoning lithium secondary battery | 辉能科技股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119768942-A | Self-poisoning lithium secondary battery | 辉能科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-110177776-B | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-119219809-A | Fluorine-containing polymer, preparation method thereof and ion exchange membrane | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-5795892-A | ANTICOAGULANTS | BOEHRINGER MANNEIM GMBH (DE) | 1998-08-18 | — | — | US | disclosed |
| EP-0805159-A1 | Phosphorus containing alkyl or arylsulphonyl derivatives and method for preparing same | Cytec Canada Inc. (CA) | 1997-11-05 | — | — | EP | disclosed |
| US-4912231-A | Reacting a proline derivative with an aromatic nucleophile in presence of a Lewis acid catalyst | E. R. SQUIBB & SONS, INC. (US) | 1990-03-27 | — | — | US | disclosed |
| US-4150051-A | N-Cyanosulfonamide compounds | CIBA-GEIGY CORPORATION (US) | 1979-04-17 | — | — | US | disclosed |
| US-4080483-A | COATINGS, MOLDING MATERIALS, LAMINATION | CIBA-GEIGY CORPORATION (US) | 1978-03-21 | — | — | US | disclosed |
| US-4075185-A | ADDITION POLYMERIZATION | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4072584-A | PIGMENTS, RUBBER | ALLIED CHEMICAL CORPORATION (US) | 1978-02-07 | — | — | US | disclosed |
| US-4049711-A | POLYSULFONAMIDE MONOMERS | CIBA-GEIGY CORPORATION (US) | 1977-09-20 | — | — | US | disclosed |
| US-3944526-A | N-cyanosulfonamide resins and intermediates therefor and products thereof | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | CA1 3553/4885CA2 1341/4885POLB 3713/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | CA1 4783/4885CA2 4314/4885POLB 1018/4885 |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | CA1 4783/4885CA2 4314/4885POLB 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.